Estudo randomizado | Fluvoxamina não é melhor que placebo em pacientes ambulatoriais com COVID-19 leve a moderada
16 Jan, 2023 | 11:12hEditorial: Lack of Benefit of Fluvoxamine for COVID-19 – JAMA
Entrevista com a autora: Fluvoxamine vs Placebo and Time to Sustained Recovery From Mild or Moderate COVID-19 – JAMA
Comentário: Trial finds that fluvoxamine doesn’t speed COVID recovery – CIDRAP
Comentário no Twitter
Among outpatients with mild to moderate #COVID19, treatment with 50 mg of fluvoxamine twice daily for 10 days, compared with placebo, did not improve time to sustained recovery. https://t.co/4QgBssqFSU pic.twitter.com/RMZ6mqlx6u
— JAMA (@JAMA_current) January 12, 2023